Data as of Q4 2025 (Dec 31, 2025)

NovaBridge Biosciences

(NBP)

Financial Statements · SEC EDGAR XBRL

Net Income
-$46.3M
-108.1%
EPS
$-0.21
-75.0%
Op. Income
-$94.3M
-83.3%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Cost of Revenues
Gross Profit
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
-
-
-
-
$13.8M
-
-
-
-
$13.8M
-
-
-
$3.9M
$7.3M
-
-
-
-
$6.5M
$62.9M
$21.8M
$21.4M
$22.5M
$190.3M
$94.3M
$51.4M
$72.6M
$51.5M
-
-$94.3M
-$51.4M
-$72.0M
-$53.1M
-
-
-
$102K
$1K
$0
-$1.7M
-$4.7M
-$8.1M
-$28.3M
$13.1M
-$88.3M
-$49.7M
-$82.2M
-$141.1M
-$366.4M
$0
$0
$0
$103K
-$495K
-$46.3M
-$22.2M
-$207.7M
-$371.1M
-$365.9M
$-0.21
$-0.12
$-1.09
$-1.96
$-2.09
$-0.21
$-0.12
$-1.09
$-1.96
$-2.09
220.3M
186.7M
191.4M
189.8M
174.7M